A phase 2 randomized controlled trial assessing the efficacy and safety of canakinumab, another IL-1 antagonist, in patients with pulmonary sarcoidosis (NCT02888080) has completed the recruitment process. The gene discussed is IL1B; the disease is pulmonary sarcoidosis.